Abbott (NYSE: ABT) has received approval from the U.S. Food and Drug Administration (FDA) for its Volt™ Pulsed Field Ablation (PFA) System for the treatment of atrial fibrillation (AFib). Following this milestone, Abbott will soon begin commercial PFA procedures in the United States. In parallel, the company will continue expanding its footprint across the European Union after securing the Volt CE Mark approval earlier this year.
Addressing a Growing Burden of Atrial Fibrillation
AFib affects nearly 12 million people in the United States over the age of 65, and this number is expected to double over the next two decades. Individuals living with AFib face a fivefold higher risk of stroke, and the condition has contributed significantly to mortality in the U.S. for more than 20 years. When medications and other therapies fail, many patients depend on minimally invasive cardiac ablation procedures to restore normal heart rhythms.
Strong Clinical Evidence Supports FDA Approval
Abbott secured FDA approval for the Volt PFA System based on compelling data from its VOLT-AF IDE study. This large clinical trial enrolled 392 patients across 40 centres in the United States, Europe, Canada, and Australia. The results demonstrated clinically meaningful safety and effectiveness outcomes in two patient populations—those with paroxysmal atrial fibrillation, characterised by intermittent episodes, and those with persistent AFib, where episodes last longer than seven days.
Physician Perspectives Highlight Clinical Advantages
Commenting on the approval, Dr DJ Lakkireddy, Executive Medical Director of the Kansas City Heart Rhythm Institute and among the first physicians in the U.S. to use Volt, emphasised the importance of early intervention in AFib management. He noted that during cardiac ablation, physicians require tools that combine strong safety profiles with procedural efficiency. According to him, Volt offers a promising solution through its real-time contact visualisation and unique balloon-in-basket design, which enhances tissue contact and delivers focused energy while addressing limitations seen in earlier PFA technologies.
Innovative Design Built Around Physician Feedback
Abbott developed the Volt PFA System by building on its established electrophysiology portfolio and incorporating direct physician input. The all-in-one system enables clinicians to map, pace, and ablate using a single catheter. Furthermore, its proprietary balloon-in-basket design offers multiple handling options, improves ease of use, and ensures efficient energy transfer directly to targeted cardiac tissue, thereby interrupting abnormal electrical signals.
Seamless Integration Improves Workflow and Precision
With workflow optimisation in mind, Abbott designed the Volt PFA System to integrate seamlessly with the EnSite™ X Electrophysiology System. This integration provides accurate three-dimensional cardiac mapping and reduces the need for multiple catheter exchanges during ablation procedures. Unlike several existing PFA systems that require repeated energy applications across various catheter positions, Volt addresses these challenges through a more streamlined and efficient approach.
Clinical Benefits for Patients and Physicians
As per the Abbott press release, Clinical studies have shown that the Volt PFA System delivers precise, targeted energy that helps create durable lesions with fewer therapy applications. As a result, patients benefit from improved first-time procedural success, reduced need for repeat ablations, and a lower risk of complications.
In addition, the system expands procedural options for patients. Physicians can perform ablations using conscious sedation rather than general anaesthesia, a significant advantage for patients who may not tolerate anaesthesia well. Moreover, the Volt PFA System reduces radiation exposure from fluoroscopy and limits haemolysis, further enhancing patient safety.
Expanding Treatment Options for Faster Recovery
According to Dr Christopher Piorkowski, Chief Medical Officer of Abbott’s electrophysiology business, physician feedback highlighted the need for effective PFA solutions that do not rely on general anaesthesia. He explained that the Volt PFA System addresses this unmet need by supporting conscious sedation while maintaining strong clinical outcomes. Consequently, patients may experience shorter procedures, faster recovery times, and broader access to minimally invasive AFib treatment.